Background: It is generally assumed that T cells do not produce active TGF-b since active TGF-b as measured in supernatants by ELISA without acidification is usually not detectable. However, it is possible that active TGF-b from T cells may take a special form which is not detectable by ELISA.
Introduction
TGF-b is an immunoregulatory cytokine that controls immune responses by multiple mechanisms [1] . TGF-b-deficient mice manifest an autoimmune syndrome and do not survive longer than 3-4 wks after birth [2] , [3] . Moreover, it has been shown that TGF-b initiates Th17 differentiation in combination with IL-6 or IL-21 [4] , [5] , [6] , [7] , [8] . Although IL-17 is a dominant factor in the induction of autoimmune diseases such as experimental autoimmune encephalomyelitis [9] and collagen-induced arthritis [10] , IL-17 production is not seen in TGF-b 1 2/2 mice [5] . Although many cell types produce TGF-b, T cell-produced TGFb is plays an important role in the control of autoimmune responses and Th17 differentiation. Thus, T cell-specific TGF-b conditional knockout mice develop fatal autoimmune disease even though they survive longer than TGF-b 2/2 mice [11] , and Th17 differentiation is hampered in these mice [11] , indicating that TGF-b produced by T cells themselves is required for Th17 differentiation.
TGF-b is produced as a pro-form (pro-TGF-b), and is intracellularly processed by furin proprotein convertase into latent TGF-b. Latent TGF-b is a non-covalently associated complex consisting of latency-associated peptide (LAP) which is the Nterminal portion of pro-TGF-b, and mature TGF-b which is made of the C-terminal of pro-TGF-b. Latent TGF-b cannot bind TGFb receptors and thus further activation processes are required for biological activity [12] . It is unknown how T cell-produced TGF-b is activated.
Murine T cell culture supernatants usually do not contain active TGF-b when measured by ELISA without acidification. Thus, it is generally believed that T cells do not produce active TGF-b.
Nakamura et al. [13] first reported that murine CD4 + CD25 + regulatory T cells (Tregs) expressed surface LAP and/or TGF-b (LAP/TGF-b), and they proposed that the membrane-bound TGF-b mediated suppressive activity of Tregs. We also confirmed that Foxp3 + Tregs express surface LAP/TGF-b by using our newly developed anti-mouse LAP/TGF-b mAbs [14] . Human FOXP3 + Tregs have also been shown to express surface LAP [15] , [16] , [17] . It is possible that surface LAP/TGF-b on T cells can trigger TGF-b signaling in target cells by a cell-cell contact manner, give that active TGF-b is usually not detectable from T cell culture supernatants by ELISA. Alternatively, active TGF-b may be a rapidly-consumed, short-lived cytokine in T cell culture. Although there is no experimental evidence thus far, it is also possible that T cells produce biologically active TGF-b in a form that is not detectable by ELISA.
Given these possibilities, we developed a bioassay system which detects TGF-b activity, rather than the specific molecular form (the 25 kDa free TGF-b dimer) that an ELISA detects. This new bioassay consists of reporter cells that have direct contact with T cells and which can sense both short-lived and membrane-bound forms of TGF-b. 293T cells were transduced with a TGF-b reporter vector which has repeated the CAGA Smad binding elements in the promoter followed by luciferase, and with CD32 (Fc receptor) and CD86.
By using the newly developed 293T-caga-Luc-CD32-CD86 reporter cells, we found that pre-activated murine CD4 T cells induced high luciferase signals in the reporter cells. Although Foxp3 + T cells expressed surface LAP/TGF-b [14] , pre-activated CD4 + CD25 2 T cells induced much higher TGF-b signal than pre-activated CD4 + CD25 + T cells. The T cell-produced TGF-b was a soluble form since T cell culture supernatants contained TGF-b activity. The T cell-produced TGF-b is not the canonical 25 kDa mature TGF-b since a TGF-b ELISA did not detect the 25 kDa mature TGF-b form in the same T cell culture supernatants. Surprisingly, the TGF-b activity in T cell culture supernatants was neutralized with an anti-LAP mAb and with an anti-pro-TGF-b/latent TGF-b mAb, but not with anti-mature TGF-b Abs. TGF-b activity remained in culture supernatants even after the culture supernatant was treated with immobilized anti-LAP mAb by which latent TGF-b detected by TGF-b ELISA after acidification was virtually all depleted. Thus, T cell-produced TGF-b takes a unique molecular form which contains LAP as a component, and from which 25 kDa mature TGF-b is not released even after acidification. T cell-produced TGF-b initiated TGF-b signaling not in all cell types, suggesting that cell typespecific factors are required to sense the T cell-produced TGF-b.
Results

Generation of a TGF-b reporter cell line
It has been reported that CAGA is a Smad binding element and a promoter assay vector containing tandem repeats of CAGA in the minimum promoter region ((caga) 12 -MLP-Luc) is a sensitive and specific TGF-b reporter vector [18] , [19] . We inserted the (caga) 12 -MLP-Luc segment into a promoterless lentiviral vector (pSMPUW) to construct a lentivirus based universal TGF-b reporter vector (pSMPUW-(caga) 12 -MLP-Luc-UbC-EGFP.puro-RRE) ( Figure 1A ).
Human embryonic kidney 293T cells were then transduced with the TGF-b reporter vector (293T-caga-Luc cells). The response curve of 293T-caga-Luc cells to recombinant TGF-b was able to detect as little as 2 pg/ml recombinant human TGF-b ( Figure 1B) . To make the 293T-caga-Luc cells function as artificial antigen presenting cells, the 293T-caga-Luc cells were transduced with mouse CD32 (Fc receptor) and mouse CD86 retroviral vectors ( Figure 1C ). Serpinb9 (granzyme B inhibitor) and Serpinb9b (granzyme M inhibitor) were also retrovirally expressed. These granzyme inhibitor genes suppressed CD4 T cell-mediated killing of CD32-and CD86-transduced mink lung epithelial cells (MLEC) (data not shown), and it is expected that the granzyme inhibitor genes protect 293T cells from CD4 T cell-mediated killing, too, although 293T cells are relatively resistant to CD4 cell-mediated killing without these gene transductions. The transduced 293T cells were cloned at each step and high responding or high expressing clones were selected. The resulting TGF-b reporter cell line is termed as 293T-caga-Luc-CD32-CD86.
Detection of TGF-b activity from CD4 T cells in coculture
We tested whether murine CD4 T cells have TGF-b activity by using the 293T-caga-Luc-CD32-CD86 TGF-b reporter cells. For these experiments we co-cultured T cells with 293T-caga-Luc-CD32-CD86 TGF-b reporter cells in presence of anti-CD3 antibody. In preliminary experiments, we found that freshly prepared CD4 T cells barely induced luciferase during 24 hr coculture. Then, we tested pre-activated CD4 T cells. Thus, mouse CD4 T cells were stimulated with plate-bound anti-CD3/CD28 for two days, rested for one day and then co-cultured with 293T-cggaLuc-CD32-CD86 TGF-b reporter cells with anti-CD3 for 16 hrs (Figure 2A ). As shown Figure 2B , CD4 T cells induced high luciferase activity in a cell number dependent manner. Interestingly, although the response to recombinant TGF-b became saturated above 200 pg/ml, CD4 T cells often induced higher luciferase activity than the saturation point. It should be noted that the restimulation at this time point minimally induced activation-induced cell death, while re-stimulation at later time points induced notable cell death under microscopic observation. Higher luciferase signal was observed at later time points when anti-FasL mAb was added to block the activation-induced cell death ( Figure S1 ). Thus, it is not likely that the TGF-b activity is generated from dying T cells.
TGF-b activity from Tregs
We previously reported that activated Fox3 + CD4 T cells express surface LAP/TGF-b using our newly developed antimouse LAP/TGF-b mAbs [14] . We tested whether these surface LAP/TGF-b-expressing Foxp3 + CD4 T cells were CD4 T cells with TGF-b activity. CD4
2 ) cells were isolated and stimulated with plate-bound anti-CD3/CD28 in the presence of IL-2 for two days and rested for one day in presence of IL-2. They were then co-cultured with 293T-caga-Luc-CD32-CD86 TGF-b reporter cells in presence of anti-CD3 and IL-2 for 16 hrs. The T cells have tight cell to cell contact with the reporter cells both by the CD32-anchored anti-CD3 Ab and by CD86; thus the reporter cells should be able to sense membrane-bound TGF-b activity if 
No requirement for direct contact with T cells for induction of TGF-b signaling
Although we initially anticipated that membrane-bound TGF-b on Foxp3
+ CD4 T cells would trigger TGF-b signaling in the reporter cells, as described above, this was not the case. To further investigate the role of membrane-bound TGF-b, we asked whether direct contact between T cells and the reporter cells was required to initiate TGF-b signaling. In order to address this question, 293T-caga-Luc cells that did not have surface CD32 or CD86 were mixed with CD32-and CD86-trandsduced 293T cells that did not have the (caga) 12 -Luc reporter ( Figure 4B ). If T-reporter contact was required to present T cell-produced TGF-b to TGF-b receptors on the reporter cells, there would be diminished induction of luciferase in this condition. We found, however, that pre-activated CD4 T cells stimulated with 293T-CD32-CD86 cells in presence of anti-CD3 induced TGF-b signaling in 293T-cagaLuc cells as well as or better than the condition in which 293T-caga-Luc-CD32-CD86 cells were used as reporter cells ( Figure 4A ). This result indicates that the T cell-produced TGF-b that results in TGF-b activity as measured in our reported system is soluble and can diffuse to adjacent cells.
TGF-b activity in T cell culture supernatants
After demonstrating that T cell-produced TGF-b is in a soluble form, we next asked whether this form accumulates in culture supernatants. To address this, pre-activated CD4 +
CD25
2 T cells (anti-CD3/28 for 3 days) were re-stimulated with the reporter cells plus anti-CD3 for 16 hrs as the co-culture assay ( Figure 5A ), and the culture supernatants were also taken at the end of the assay. The culture supernatants were added to fresh 293T-caga-Luc-CD32-CD86 TGF-b reporter cells (without live T cells), and the reporter cells were cultured for 9 hrs ( Figure 5B ). We found that the T cell culture supernatant from the 1610 5 cells/well induced luciferase activity equivalent to approximately 200 pg/ml of recombinant human TGF-b. Thus, TGF-b activity accumulates in T cell culture supernatants. We also measured the same culture supernatant by TGF-b ELISA without acidification which detects the 25 kDa free TGF-b dimer and found that the amount of active TGF-b as measured by the TGF-b ELISA was 10 pg/ml. ''Total'' TGF-b as measured by ELISA after acidification was found to be 486 pg/ml (Table 1) . These results indicate that the T cellproduced TGF-b activity takes an unconventional form which is different from the 25 kDa free TGF-b dimer and is not detectable by ELISA.
T cell-produced TGF-b activity induces Smad2 phosphorylation in 293T-caga-Luc-CD32-CD86 cells
To confirm that the luciferase activity was a consequence of TGF-b signaling, we determined Smad2 phosphorylation in 293T-caga-Luc-CD32-CD86 cells after exposure to T cell culture supernatants. T cell culture supernatants from anti-CD3/CD28-stimulated cultures of pre-activated CD4 + CD25 2 T cells contained higher TGF-b activity (2-3 ng/ml recombinant TGF-b equivalent) than cultures re-stimulated with 293T-caga-Luc-CD32-CD86 reporter cells/anti-CD3 (data not shown). Thus, we used culture supernatants from plate-bound anti-CD3/CD28 re-stimulated CD4 + CD25 2 T cells for further studies. 1 ng/ml recombinant human TGF-b or a diluted T cell culture supernatant adjusted to the equivalent TGF-b activity determined by the 293T-caga-Luc-CD32-CD86 TGF-b bioassay was added to 293T-caga-Luc-CD32-CD86 cells for the indicated time, and the cell lysates were run on SDS-PAGE and blotted with anti-phospho-Smad2 antibody. Although the T cell culture supernatant was diluted to normalize the TGF-b activity, the T cell culture supernatant induced stronger Smad2 phosphorylation than recombinant TGF-b at all the time points ( Figure 6 ). This result suggests that T cell-produced TGF-b activity is qualitatively different from the 25 kDa free TGF-b dimer. 2 T cells were stimulated with plate-bound anti-CD3/ CD28 for 2 days, and rested for 1 day in presence of 100 U/ml IL-2. These pre-activated CD4 T cells were recovered, and the indicated numbers of T cells were added to 293T-caga-Luc-CD32-CD86 cells with 0.5 mg/ml anti-CD3 antibody and 100 U/ml IL-2 for 16 hrs after which luciferase activity was measured. Error bars represent mean 6 S.D. of duplicates. doi:10.1371/journal.pone.0018365.g003
T cell-produced TGF-b activity is not found in the ELISA detectable ''total'' TGF-b fraction TGF-b measured by ELISA after acidification is termed ''total'' TGF-b. This is based on the assumption that following acidification, the 25 kDa free TGF-b dimer is released from any form of TGF-b, such as the small latent TGF-b complex and the large latent TGF-b complexes. We thus asked whether T-cell produced TGF-b activity resides in the ''total'' TGF-b fraction. Since FBS-derived latent TGF-b affects TGF-b ELISA after acidification, we used TGF-bdepleted FBS for the culture medium [20] . The background bovine TGF-b remaining in the 10% TGF-b-depleted FBS-supplemented medium was 148 pg/ml. We treated a T cell culture supernatant with anti-LAP mAb TW7-16B4-coupled magnetic beads (or an IgG 1 isotype control mAb MOPC21) to deplete latent TGF-b in the supernatant. The amount of ''total'' TGF-b detected by ELISA after acidification in control MOPC21-treated T cell culture supernatant was 1,318 pg/ml, whereas the anti-LAP TW7-16B4-treated T cell culture supernatant contained 126 pg/ml ''total'' TGF-b ( Figure 7A ). Since anti-murine LAP TW7-16B4 mAb does not cross-react with bovine LAP (data not shown), we conclude that all T cell-derived ''total'' TGF-b was removed by the TW7-16B4-coupled magnetic bead treatment. However, TGF-b activity in the TW7-16B4-treated T cell culture supernatant was intact since the anti-LAP TW7-16B4-treated T cell culture supernatant induced an identical TGF-b response in 293T-caga-Luc-CD32-CD86 reporter cells as the control MOPC21-treated T cell culture supernatant Table 1 . TGF-b in a T cell culture supernatant was measured by the 293T-caga-CD32-CD86-caga bioassay (TGF-b activity), by ELISA without acidification (the 25 kDa free TGF-b dimer), and by ELISA after acidification ( ''total TGF-b'').
TGF-b in culture supernatant
293T-(caga) 12 produced TGF-b activity as measured by the 293T-caga-Luc-CD32-CD86 bioassay takes a molecular form that contains LAP as a component. Since anti-LAP mAb TW7-20B9 does not crossreact with human LAP (Figure S2 ), the new form of active TGF-b is truly produced from murine CD4 T cells, but not from the human 293T reporter cells.
T cell-produced TGF-b is not latent TGF-b
Since the T cell-produced TGF-b contains LAP, it may simply represent the latent TGF-b complex and the 293T-caga-Luc-CD32-CD86 reporter cells have a TGF-b activation machinery which can initiate TGF-b signaling in response to latent TGF-b. To exclude this possibility, we added a commercially available recombinant human latent TGF-b or a culture supernatant of mouse TGF-b-transduced P3U1 cells to the 293T-caga-Luc-CD32-CD86 reporter cells. We found that mouse TGF-b-transduced P3U1 cells produced high amounts of latent TGF-b, as judged by a TGF-b ELISA with or without acidification. However, both latent TGF-b samples barely induced TGF-b signaling in the 293T-cagaLuc-CD32-CD86 cells (Figure 9 ). Even at 4,000 pg/ml, recombinant human latent TGF-b and mouse latent TGF-b-containing supernatants induced only faint luciferase signals (equivalent to less than 10 pg/ml recombinant TGF-b), which is likely explained by the presence of contaminating active TGF-b which was detected by ELISA without acidification (data not shown).
Cell type-specific responses to T cell-produced TGF-b
Since T cell-produced TGF-b activity takes an unconventional TGF-b form, it is possible that it requires specific sensing machineries and that only certain cell types respond to T cellproduced TGF-b. To test this, we assayed T cell culture supernatants on other TGF-b reporter cell lines. The Mv1Lu-(caga) 12 -Luc cell line has the same the (caga) 12 -Luc reporter as the 293T-caga-Luc-CD32-CD86 cell line, and responds to recombinant TGF-b in a dose-dependent manner. However, we found that Mv1Lu-(caga) 12 -Luc cells did not respond to T cell culture supernatants (Figure 10, middle) . Another well-known TGF-b bioassay reporter line is the mink lung epithelial cell (MLEC)-PAI-1-Luc cell line which has a PAI-1 promoter-driven luciferase reporter [21] ; we found that MLEC-PAI-1-Luc cells also did not respond to T cell-produced TGF-b (Figure 10, bottom) . These results indicate that T cell-produced TGF-b does not initiate TGFb signaling in all cell types, but it requires cell type-specific molecular machineries to initiate TGF-b signaling.
Discussion
We have previously reported [22] a TGF-b bioassay for T cells using the MLEC-PAI-1-Luc cell line, in which T cells were cocultured with reporter cells and stimulated with anti-CD3/CD28-coated beads attached to the reporter cell surface. This bioassay 12 -Luc). 293T cells were transduced with (caga) 12 -Luc, mouse CD32 and mouse CD86. Serpinb9 and Serpinb9b were also transduced as we found in preliminary experiments that these granzyme inhibitor genes acted to lessen CD4-mediated killing in MLEC-PAI-1-Luc cells. When we used this new 293T-caga-Luc-CD32-CD86 reporter cell to assay activated T cells, we found that activated T cells produced high TGF-b activity in the 293T-caga-Luc-CD32-CD86 reporter cell assay even though we could not detect active TGF-b production by ELISA. Furthermore, we found that activated Foxp3 + CD4 T cells that express surface LAP/TGF-b [14] had lower TGF-b activity in the 293T-caga-Luc-CD32-CD86 reporter cell assay than activated CD25 2 T cells. This TGF-b activity was detected in T cell culture supernatants indicating that the T cellproduced TGF-b was in the soluble form and was not membranebound. These findings are in contrast to our previous observations using MLEC-PAI-1-Luc cells [22] that when compared to CD4 + CD25 2 T cells, activated CD4 + CD25 + T cells had higher TGF-b activity and this activity was linked to membrane bound TGF-b. We believe that this difference is because the T cellproduced TGF-b activity we observed using the 293T-caga-Luc-CD32-CD86 reporter cell assay consists of an unconventional form of TGF-b which can be measured by the 293T-caga reporter cells but not by MLEC-PAI-1-Luc cells. Thus it appears that Foxp3 + Tregs produce the canonical form of mature TGF-b which can be neutralized with anti-TGF-b mAb 1D11, whereas Foxp3 2 non-Tregs produce a new form of TGF-b which we have identified with our new reporter assay and which can induce TGF-b signaling in a cell type-specific manner.
Whether all activated CD4
+ CD25 2 T cells produce this newly described form of TGF-b or it is produced by a subset of CD4 + CD25 2 cells is an important question. In addressing this question, we found that CD4 T cells that produce this new form of TGF-b reside primarily in the CD62L 2 CD44 hi memory fraction as opposed to the CD62L + CD44 lo naive fraction ( Figure S3 ). Whether differentiated Th cell subsets such as Th1, Th2, Th17, or Tr1 cells preferentially produce this form of TGF-b is an interesting future question.
The At this time we do not know what cell properties and/or molecules are required to initiate TGF-b signaling by the new form of TGF-b we have identified. In preliminary experiments, we did not find that T cell-produced TGF-b induced Smad2 phosphorylation in CD4 T cells or in bone marrow-derived DCs. However, it is possible that sub-populations of T cells or DCs would respond T cell-produced TGF-b under special conditions.
In conclusion, our work demonstrates that murine CD4 T cells produce an unconventional form of TGF-b which has biological activity as measured by 293T-caga-Luc-CD32-CD86 reporter cells but not by other assay systems and is not produced in significant amounts by conventional Treg cells. Our finding of a new form of T cell-produced TGF-b and the newly developed TGF-b bioassay system will provide a new avenue to investigate T cell function of the immune system.
Materials and Methods
Cell lines, Plasmids, and antibodies
The (caga) 12 12 -MLP-Luc segment into a promoterless lentiviral vector pSMPUW (Cell Biolabs) along with ubiquitin C promoter-driven a GFP-puro fusion gene as a selection marker (pSMPUW-(caga) 12 -Luc). pMCs retroviral vector was kindly provided Dr. T. Kitamura (Tokyo Univ., Tokyo, Japan) and pBMN retroviral vector was from Addgene under a MTA with Stanford University (Stanford, CA). A lentivirus supernatant and retrovirus supernatants were produced as described previously [23] . Human embryonic kidney 293T cells (Clontech) were sequentially transduced with pSMPUW-(caga) 12 Luc, pBMN-mouse CD32 (without IRES), pBMN-mouse CD86 (without IRES), pMCs-Serpinb9-IRES-Thy1.1, and pMCs-Serpinb9b-IRES-Thy1.2 vectors with cloning in each step. The resultant cells were termed 293T-caga-Luc-CD32-CD86 cells. Anti-TGF-b hybridoma 1D11 was from ATCC, and chicken anti-TGF-b (AF-101-NA) was from R&D Systems. Anti-mouse LAP mAbs TW7-16B4 and TW7-20B9, and anti-latent TGF-b/pro-TGF-b mAb TW7-28G11 were described previously [14] . AntiFasL (clone MFL3) was from BioLegend. ALK5 inhibitor II was from EMD/Calbiochem.
CD4 T cell preparation and stimulation
Mice were housed in a pathogen-free environment and the animal protocols were approved by the Committee on Animals of Harvard Medical School (Harvard Medical Area Standing Committee on Animals, Protocol No. 02683). CD4 T cells were separated from BALB/c mice (The Jackson Laboratories) using a MACS CD4 purification kit (Miltenyi Biotec). When CD4 + CD25 2 T cells were prepared, biotinylated anti-CD25 antibody (7D4, BD Biosciences) was additionally mixed to the MCAS antibody cocktail. CD4 + CD25 + T cells were prepared from the CD4 fraction by staining CD25-FITC (7D4, BD Biosciences) followed by anti-FITC MACS beads (Miltenyi Biotec), and by MS column separation. T cells were stimulated with plate-bound anti-CD3 and anti-CD28 (5 mg/ul each) for 2 days in 10% FBS-supplemented IMDM. In case of CD4 + CD25 + T cell stimulation, 100 U/ml recombinant IL-2 was added both in CD4 + CD25 + T cell cultures and in CD4 + CD25 2 T cell cultures. The cells were split into non-coated wells and rested for 1 day. The cells were recovered, washed with the culture medium, counted, and used for the TGF-b bioassay, or re-stimulated with platebound anti-CD3/CD28 for 24 h hrs for culture supernatants. When indicated, TGF-b-depleted FBS [20] was used for the culture medium.
TGF-b ELISA
TGF-b ELISA was performed using anti-TGF-b mAb 1D11 as a coating antibody and biotinylated chicken anti-TGF-b IgY (BAF240, R&D Systems) as a detection antibody. Recombinant human TGF-b (R&D Systems) was used as a standard (0-2,000 pg/ml). Sample acidification was done by adding 1/10 volume of 1 N HCl, incubating at room temperature for 10 min, and neutralizing with 1/10 volume of 1 N NaOH/0.1 M Tris. The samples were then diluted twofold by adding 25 mM Tris buffered saline.
TGF-b bioassay
293T-caga-Luc-CD32-CD86 TGF-b reporter cells were seeded at 2610 4 cells/100 ml/well on collagen-coated 96-well plates 1 day before addition of T cells. On the day of assay, 10 ml of 1 mg/ml anti-CD3 (145-2C11) (BD Biosciences) was added to each well (final 0.5 mg/ml). When CD4 + CD25 + T cells were tested, IL-2 was also added to final 100 U/ml. Pre-activated CD4 T cells or recombinant human TGF-b (R&D Systems) were added at 100 ml/well (final total volume 210 ml/well) and cultured for 16 hrs. Similarly, the TGF-b bioassay from culture supernatants was conducted by adding 100 ml of diluted T cell culture supernatants to 293T-caga-Luc-CD32-CD86 cell culture wells and the reporter cells were cultured for the indicated time. When neutralizing antibodies were tested, T cell culture supernatants were diluted to be equivalent to 200 pg/ml recombinant TGF-b activity and were then premixed with the antibodies at 100 mg/ml for 30 min at room temperature. 100 ml of the mixture was added to 100 ml of 293T-caga-Luc-CD32-CD86 reporter wells. 293T-caga-Luc-CD32-CD86 cells were lysed with Glo-Lysis buffer (Promega), and luciferase activity was measured by ONE-Glo luciferease assay reagent (Promega).
Detection of Smad2 phosphorylation
293T-caga-Luc-CD32-CD86 cells were exposed to recombinant human TGF-b (1 ng/ml) or a T cell culture supernatant diluted by TGF-b activity determined by the 293T-caga-Luc-CD32-CD86 bioassay equivalent to 1 ng/ml TGF-b. After 2, 5, 15, and 30 min, the cells were lysed with 1% Triton X-100, 0.25% deoxycholate, 0.1% SDS, 1 mM NaVO 4 , protease inhibitor cocktail (Pierce/Thermo), 25 mM Tris buffered saline. The lysates were clarified by centrifugation at 13,000 rpm for 15 min, and run on SDS-PAGE under reducing conditions. Western blot was conducted with rabbit anti-phospho-Smad2(Ser465/467) antibody (Cell Signaling) and with rabbit anti-Smad2/3 antibody (Cell Signaling).
Depletion of ''total'' TGF-b from culture supernatants with an anti-LAP Ab 400 ml of 1 mg/ml of anti-mouse IgG magnetic beads (BioMag Plus, Polysciences) was placed in a 1.5 ml microcentrifuge tube and the beads were washed with PBS three times. 400 ml PBS containing 20 mg of anti-mouse LAP mAb TW7-16B4 or isotype control MOPC21 was added to the beads and incubated with rotation for 4 hrs. After washing with PBS three times, 0.6 ml of the T cell culture supernatant from plate-bound anti-CD3/CD28 re-stimulated CD4 +
CD25
2 T cells in 10% TGF-b-depleted FBS IMDM was added to the bead pellets, and incubated at 4uC for overnight. The unbound supernatant was recovered by magnetic separation. The amount of TGF-b before and after separation was measured by TGF-b ELISA after acidification.
Latent TGF-b
Recombinant human latent TGF-b was purchased from R&D Systems. Recombinant mouse latent TGF-b was made as a culture supernatant of mouse Tgfb1-transduced P3U1 cells. The 16 culture supernatant contained 84 ng/ml total TGF-b (mostly latent TGF-b) and 142 pg/ml active TGF-b determined by TGFb ELISA with, and without acidification, respectively. Author Contributions
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